These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 9017356)

  • 1. Time-action profile of inhaled insulin.
    Heinemann L; Traut T; Heise T
    Diabet Med; 1997 Jan; 14(1):63-72. PubMed ID: 9017356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intramuscular versus subcutaneous injection of soluble and lispro insulin: comparison of metabolic effects in healthy subjects.
    Rave K; Heise T; Weyer C; Herrnberger J; Bender R; Hirschberger S; Heinemann L
    Diabet Med; 1998 Sep; 15(9):747-51. PubMed ID: 9737803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of pharmacokinetic and pharmacodynamic properties of single-dose oral insulin spray and subcutaneous insulin injection in healthy subjects using the euglycemic clamp technique.
    Cernea S; Kidron M; Wohlgelernter J; Modi P; Raz I
    Clin Ther; 2004 Dec; 26(12):2084-91. PubMed ID: 15823772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhaled micronized crystalline human insulin using a dry powder inhaler: dose-response and time-action profiles.
    Rave K; Nosek L; Heinemann L; Gonzales C; Ernest CS; Chien J; Muchmore D
    Diabet Med; 2004 Jul; 21(7):763-8. PubMed ID: 15209771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Technosphere/Insulin--proof of concept study with a new insulin formulation for pulmonary delivery.
    Steiner S; Pfützner A; Wilson BR; Harzer O; Heinemann L; Rave K
    Exp Clin Endocrinol Diabetes; 2002 Jan; 110(1):17-21. PubMed ID: 11835120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intra-individual variability of the metabolic effect of inhaled insulin together with an absorption enhancer.
    Heinemann L; Klappoth W; Rave K; Hompesch B; Linkeschowa R; Heise T
    Diabetes Care; 2000 Sep; 23(9):1343-7. PubMed ID: 10977030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of subcutaneously administered U40 and U100 formulations of regular human insulin.
    Heinemann L; Chantelau EA; Starke AA
    Diabete Metab; 1992; 18(1):21-4. PubMed ID: 1563532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with Type 1 diabetes.
    Bott S; Tusek C; Jacobsen LV; Endahl L; Draeger E; Kapitza C; Heise T
    Diabet Med; 2006 May; 23(5):522-8. PubMed ID: 16681561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smoking enhances absorption of insulin but reduces glucodynamic effects in individuals using the Lilly-Dura inhaled insulin system.
    Wise S; Chien J; Yeo K; Richardson C
    Diabet Med; 2006 May; 23(5):510-5. PubMed ID: 16681559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PROMAXX inhaled insulin: safe and efficacious administration with a commercially available dry powder inhaler.
    Heise T; Brugger A; Cook C; Eckers U; Hutchcraft A; Nosek L; Rave K; Troeger J; Valaitis P; White S; Heinemann L
    Diabetes Obes Metab; 2009 May; 11(5):455-9. PubMed ID: 19236443
    [TBL] [Abstract][Full Text] [Related]  

  • 11. U-100, pH-Neutral formulation of VIAject(®) : faster onset of action than insulin lispro in patients with type 1 diabetes.
    Heinemann L; Nosek L; Flacke F; Albus K; Krasner A; Pichotta P; Heise T; Steiner S
    Diabetes Obes Metab; 2012 Mar; 14(3):222-7. PubMed ID: 21981286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects.
    Becker RH; Frick AD; Burger F; Potgieter JH; Scholtz H
    Exp Clin Endocrinol Diabetes; 2005 Sep; 113(8):435-43. PubMed ID: 16151977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AIR inhaled insulin in subjects with chronic obstructive pulmonary disease: pharmacokinetics, glucodynamics, safety, and tolerability.
    Rave K; de la Peña A; Tibaldi FS; Zhang L; Silverman B; Hausmann M; Heinemann L; Muchmore DB
    Diabetes Care; 2007 Jul; 30(7):1777-82. PubMed ID: 17456839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of particle size and aerosolization time on the metabolic effect of an inhaled insulin aerosol.
    Kapitza C; Heise T; Fishman RS; Shapiro DA; Gopalakrishnan V; Rave K; Bott S; Perera AD; Heinemann L
    Diabetes Technol Ther; 2004 Apr; 6(2):119-27. PubMed ID: 15117578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-response relationship of an oral insulin spray in six patients with type 1 diabetes: a single-center, randomized, single-blind, 5-way crossover study.
    Cernea S; Kidron M; Wohlgelernter J; Raz I
    Clin Ther; 2005 Oct; 27(10):1562-70. PubMed ID: 16330292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time-action profile of an oral enteric insulin formulation in healthy Chinese volunteers.
    Li J; Wang Y; Han L; Sun X; Yu H; Yu Y
    Clin Ther; 2012 Dec; 34(12):2333-8. PubMed ID: 23195963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Time-action profiles of the intermediate-acting insulin analogue des(64,65)-human proinsulin.
    Heinemann L; Heise T; Klepper A; Ampudia J; Bender R; Starke AA
    Diabete Metab; 1995 Dec; 21(6):415-9. PubMed ID: 8593922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the time-action profiles of U40- and U100-regular human insulin and the rapid-acting insulin analogue B28 Asp.
    Heinemann L; Weyer C; Rave K; Stiefelhagen O; Rauhaus M; Heise T
    Exp Clin Endocrinol Diabetes; 1997; 105(3):140-4. PubMed ID: 9228509
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin.
    Rave K; Potocka E; Heinemann L; Heise T; Boss AH; Marino M; Costello D; Chen R
    Diabetes Obes Metab; 2009 Jul; 11(7):715-20. PubMed ID: 19476477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral spray insulin in treatment of type 2 diabetes: a comparison of efficacy of the oral spray insulin (Oralin) with subcutaneous (SC) insulin injection, a proof of concept study.
    Guevara-Aguirre J; Guevara M; Saavedra J; Mihic M; Modi P
    Diabetes Metab Res Rev; 2004; 20(6):472-8. PubMed ID: 15386822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.